Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
04
2023
accepted:
21
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Disulfiram and hydralazine have recently been reported to have anti-cancer action, and repositioned to be used as adjuvant in cancer therapy. Chemotherapy combined with other medications, such as those that affect the immune system or epigenetic cell profile, can overcome resistance with fewer adverse effects compared to chemotherapy alone. In the present study, a combination of doxorubicin (DOX) with hydrazine (Hyd) and disulfiram (Dis), as a triple treatment, was evaluated against wild-type and DOX-resistant MCF-7 breast cancer cell line. Both wild-type MCF-7 cell line (MCF-7_WT) and DOX-resistant MCF-7 cell line (MCF-7_DoxR) were treated with different combination ratios of DOX, Dis, and Hyd followed by measuring the cell viability using the MTT assay. Synergism was determined using a combination index, isobologram analysis, and dose-reducing index. The anti-proliferation activity and mechanism of the triple combination were investigated by apoptosis analysis. The results showed a reduction in the IC50 values of DOX in MCF-7_WT cells (from 0.24 μM to 0.012 μM) and MCF-7_DoxR cells (from 1.13 μM to 0.44 μM) when treated with Dis (0.03μM), and Hyd (20μM) combination. Moreover, The triple combination DOX/Hyd/Dis induced significant apoptosis in both MCF-7_WT and MCF-7_DoxR cells compared to DOX alone. The triple combination of DOX, Dis, and Hyd showed a synergistic drugs combination to decrease the DOX dose needed to kill both MCF-7_WT and MCF-7_DoxR cancer cells and enhanced chemosensitivity to DOX.
Identifiants
pubmed: 37768997
doi: 10.1371/journal.pone.0291981
pii: PONE-D-23-12458
pmc: PMC10538757
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291981Informations de copyright
Copyright: © 2023 Lafi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Proc Am Thorac Soc. 2005;2(4):282-9; discussion 290-1
pubmed: 16267349
Int J Mol Sci. 2019 Sep 26;20(19):
pubmed: 31561494
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):
pubmed: 27194046
PLoS One. 2014 Feb 10;9(2):e87366
pubmed: 24520330
Trends Pharmacol Sci. 2019 Oct;40(10):774-789
pubmed: 31515079
Oncol Rep. 2017 Nov;38(5):2587-2596
pubmed: 29048620
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Cancer Drug Resist. 2019;2:141-160
pubmed: 34322663
Int J Mol Sci. 2021 May 10;22(9):
pubmed: 34068765
Cancers (Basel). 2020 Jan 09;12(1):
pubmed: 31936526
Nature. 2004 May 27;429(6990):457-63
pubmed: 15164071
Int J Breast Cancer. 2013;2013:137414
pubmed: 23864953
Clin Epigenetics. 2019 Dec 2;11(1):174
pubmed: 31791394
Exp Mol Med. 2017 Apr 28;49(4):e321
pubmed: 28450735
Exp Mol Med. 2020 Feb;52(2):192-203
pubmed: 32060354
Front Pharmacol. 2022 Dec 16;13:1072651
pubmed: 37077808
Methods Mol Biol. 2010;596:467-88
pubmed: 19949937
Mar Drugs. 2019 Sep 16;17(9):
pubmed: 31527453
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518036
Ann Oncol. 2007 Sep;18(9):1529-38
pubmed: 17761710
Nat Med. 2012 Nov;18(11):1639-42
pubmed: 23104132
Biomed Pharmacother. 2016 Oct;83:397-406
pubmed: 27424321
Front Pharmacol. 2013 Aug 01;4:89
pubmed: 23914174
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell. 1994 Aug 26;78(4):539-42
pubmed: 8069905
PLoS One. 2022 Apr 6;17(4):e0265497
pubmed: 35385506
Sci Rep. 2020 Feb 26;10(1):3470
pubmed: 32103105
Cancer Drug Resist. 2020 Mar 19;3(1):113-116
pubmed: 35582041
Anticancer Agents Med Chem. 2016;16(11):1378-1384
pubmed: 27141876
Cell Cycle. 2013 Sep 15;12(18):3013-24
pubmed: 23974104
Br J Cancer. 2013 Oct 1;109(7):1876-85
pubmed: 24008666
Asia Pac J Clin Oncol. 2022 Feb;18(1):19-27
pubmed: 32964588
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646
pubmed: 36370105
Biochem J. 2019 Apr 10;476(7):1083-1104
pubmed: 30971458
Anticancer Res. 2016 Jan;36(1):1-4
pubmed: 26722021
Cell Biosci. 2019 Jun 18;9:50
pubmed: 31244991
Int J Mol Sci. 2020 May 02;21(9):
pubmed: 32370233
Front Oncol. 2020 Nov 18;10:605386
pubmed: 33312959
PLoS One. 2006 Dec 20;1:e98
pubmed: 17183730
J Exp Clin Cancer Res. 2019 Apr 8;38(1):150
pubmed: 30961642
Int J Mol Sci. 2019 Jul 28;20(15):
pubmed: 31357721
J Transl Med. 2006 Feb 28;4:10
pubmed: 16507100
Oncotarget. 2016 Apr 19;7(16):21875-86
pubmed: 26942461
Breast. 2022 Dec;66:15-23
pubmed: 36084384
Cancer Drug Resist. 2019 Jun 19;2(2):297-312
pubmed: 35582717
Mol Cancer Ther. 2007 Mar;6(3):1089-98
pubmed: 17363502
Front Oncol. 2020 Mar 05;10:265
pubmed: 32195185
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Mol Cancer Ther. 2002 Jan;1(3):197-204
pubmed: 12467214
BMC Cell Biol. 2011 Jan 13;12:2
pubmed: 21226962
Ann Transl Med. 2016 Dec;4(24):518
pubmed: 28149880
J Transl Med. 2006 Aug 07;4:32
pubmed: 16893460
Signal Transduct Target Ther. 2023 Feb 17;8(1):70
pubmed: 36797231
Biomater Sci. 2020 Jun 21;8(12):3310-3319
pubmed: 32400782
Drug Discov Today. 2020 Jun;25(6):1099-1108
pubmed: 32320854
Adv Exp Med Biol. 2017;1026:59-104
pubmed: 29282680
Biomed Pharmacother. 2020 Jun;126:110048
pubmed: 32145587
Front Oncol. 2022 Jun 23;12:891652
pubmed: 35814435
Int J Pharm. 2020 Apr 30;580:119191
pubmed: 32142738
Sci Rep. 2016 Mar 10;6:22847
pubmed: 26961701
Ann Oncol. 2009 May;20(5):816-27
pubmed: 19153118
Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188866
pubmed: 36842765
Redox Biol. 2021 Oct;46:102122
pubmed: 34482117
Oncotarget. 2015 Dec 1;6(38):40907-19
pubmed: 26517513
Front Cell Dev Biol. 2021 Apr 20;9:645518
pubmed: 33959607